NASDAQ: CHRS | Healthcare / Biotechnology / USA |
2.18 | +0.0700 | +3.32% | Vol 3.77M | 1Y Perf -67.93% |
Nov 29th, 2023 16:00 DELAYED |
BID | 2.17 | ASK | 2.20 | ||
Open | 2.15 | Previous Close | 2.11 | ||
Pre-Market | - | After-Market | 2.20 | ||
- - | 0.02 0.88% |
Target Price | 17.25 | Analyst Rating | Moderate Buy 1.67 | |
Potential % | 691.28 | Finscreener Ranking | ★★ 45.47 | |
Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ☆ 32.27 | |
Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★ 39.26 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 7.84 | Earnings Rating | Strong Buy | |
Market Cap | 242.77M | Earnings Date | 6th Nov 2023 | |
Alpha | -0.01 | Standard Deviation | 0.16 | |
Beta | 0.87 |
Today's Price Range 2.132.34 | 52W Range 1.4310.99 | 5 Year PE Ratio Range -2.7019.20 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 7.92% | ||
1 Month | -27.57% | ||
3 Months | -58.40% | ||
6 Months | -47.47% | ||
1 Year | -67.93% | ||
3 Years | -88.19% | ||
5 Years | -80.29% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -17.36 | |||
ROE last 12 Months | -4 085.49 | |||
ROA (5Y Avg) | -2.28 | |||
ROA last 12 Months | -47.25 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -53.53 | |||
Return on invested Capital Q | -18.16 | |||
Return on invested Capital Y | -7.49 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 1.70 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-2.70 | ||||
73.19 | ||||
4.22 | ||||
20.10 | ||||
-5.20 | ||||
-2.50 | ||||
-7.67 | ||||
-1.25 | ||||
939.02M | ||||
Forward PE | -2.86 | |||
PEG | 3.59 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.20 | ||||
2.60 | ||||
0.97 | ||||
34.25 | ||||
-8.60 | ||||
Leverage Ratio | -14.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
71.60 | ||||
-104.50 | ||||
-103.00 | ||||
- | ||||
-99.13 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
165.69M | ||||
2.13 | ||||
63.96 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | -0.45 | -0.38 | 15.56 |
Q02 2023 | -0.66 | -0.49 | 25.76 |
Q01 2023 | -0.77 | -0.89 | -15.58 |
Q04 2022 | -0.87 | -0.76 | 12.64 |
Q03 2022 | -0.79 | -1.11 | -40.51 |
Q02 2022 | -0.96 | -0.65 | 32.29 |
Q01 2022 | -0.80 | -1.24 | -55.00 |
Q04 2021 | -0.61 | -0.60 | 1.64 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | -0.32 | -357.14 | Negative |
12/2023 QR | -0.07 | 0.00 | - |
12/2023 FY | -2.17 | -10.15 | Negative |
12/2024 FY | -0.72 | -2 500.00 | Negative |
Next Report Date | - |
Estimated EPS Next Report | -0.45 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 3.77M |
Shares Outstanding | 111.36K |
Shares Float | 99.13M |
Trades Count | 17.64K |
Dollar Volume | 8.41M |
Avg. Volume | 4.45M |
Avg. Weekly Volume | 2.47M |
Avg. Monthly Volume | 6.74M |
Avg. Quarterly Volume | 4.13M |
Coherus BioSciences Inc. (NASDAQ: CHRS) stock closed at 2.18 per share at the end of the most recent trading day (a 3.32% change compared to the prior day closing price) with a volume of 3.77M shares and market capitalization of 242.77M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 317 people. Coherus BioSciences Inc. CEO is Dennis M. Lanfear.
The one-year performance of Coherus BioSciences Inc. stock is -67.93%, while year-to-date (YTD) performance is -72.47%. CHRS stock has a five-year performance of -80.29%. Its 52-week range is between 1.4301 and 10.9907, which gives CHRS stock a 52-week price range ratio of 7.84%
Coherus BioSciences Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 73.19, a price-to-sale (PS) ratio of 4.22, a price to cashflow ratio of 20.10, a PEG ratio of 3.59, a ROA of -47.25%, a ROC of -53.53% and a ROE of -4 085.49%. The company’s profit margin is -99.13%, its EBITDA margin is -103.00%, and its revenue ttm is $165.69 Million , which makes it $2.13 revenue per share.
Of the last four earnings reports from Coherus BioSciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Coherus BioSciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Coherus BioSciences Inc. is Moderate Buy (1.67), with a target price of $17.25, which is +691.28% compared to the current price. The earnings rating for Coherus BioSciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Coherus BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Coherus BioSciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.44, ATR14 : 0.30, CCI20 : -38.40, Chaikin Money Flow : -0.19, MACD : -0.37, Money Flow Index : 36.53, ROC : 3.94, RSI : 41.46, STOCH (14,3) : 48.57, STOCH RSI : 1.00, UO : 48.41, Williams %R : -51.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Coherus BioSciences Inc. in the last 12-months were: Lanfear Dennis (Option Excercise at a value of $425 915), Lanfear Dennis (Sold 223 100 shares of value $450 662 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Strong Buy | Strong Buy |
Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.
CEO: Dennis M. Lanfear
Telephone: +1 650 649-3530
Address: 333 Twin Dolphin Drive, Redwood City 94065, CA, US
Number of employees: 317
Tue, 26 Sep 2023 10:11 GMT Analysts Are Bullish on Top Healthcare Stocks: Coherus Biosciences (CHRS), Qiagen (QGEN)
- TipRanks. All rights reserved.Mon, 07 Aug 2023 02:27 GMT Coherus Biosciences (CHRS) Gets a Buy from Truist Financial
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.